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Abstract
Objective: As its central basis for research, the Compe-
tence Network for HIV/AIDS (KompNet) estab-
lished a nationwide cohort study on HIV-positive pa-
tients being in medical care in Germany. In this paper,
we describe the epidemiological composition, and
clinical as well as treatment characteristics of the
KompNet cohort over time.
Methods: The KompNet cohort is an open, retrospec-
tive and prospective, multi-center, disease-specific and
nationwide cohort study that started gathering data in
June 2004. Semiannually, follow up visits of the pa-
tients are documented, covering a wide range of clini-
cal and sociodemographic data. At enrolment and
three years afterwards, an EDTA-sample is taken; a
serum-sample is taken at every follow up.
Results: As of 20.10.2008, a total of 15,541 patients
were enrolled by 44 documenting sites. In September
2007, the cohort size was reduced to ten outpatient
clinics and fifteen private practitioners, covering a total
of 9,410 patients. The documentation of these pa-
tients comprised 24,117 years of follow up-time since
enrolment (mean: 2.6 years), 62,862 person years in-
clusive data documented retrospectively on course of
HIV-infection and antiretroviral therapy (ART, mean:
6.7 years). Due to the short period of recruitment till
now, rates of death (0.3%-0.8%) and losses to follow
up (1.1%-5.5%) were low.
84.9% of patients were men. Main risk of transmis-
sion was sex between men (MSM: 62.9%). Mean age
was 45 years. About two third of patients were classi-
fied as CDC-stage B or C. Therapy regimens of cur-
rently treated patients complied with recent guidelines.
Trends of mean CD4 cell count/ﾵl regarding the ini-
tial therapy and concerning the population under
treatment reflected the developments and the chang-
ing standards of antiretroviral therapy over time.
Conclusion: The KompNet cohort covers about a
quarter of all patients estimated as being under treat-
ment in Germany. Its composition can be accounted
approximately representative for the situation of clini-
cal care and treatment in the scope of HIV/AIDS in
Germany. Therefore, it is an important instrument for
measuring the course of HIV/AIDS, the reality of use
of antiretroviral therapy and its clinical and psychoso-
cial outcomes in Germany.
Key words: Cohort Study, HIV/AIDS, Germany, Epi-
demiology, Clinical Research, Profile, Competence
Network HIV/AIDS
INTRODUCTION
In 2004, the German Competence Network for
HIV/AIDS (KompNet) started enrolment of patients
for its nationwide cohort study on HIV-positive pa-
tients [1]. KompNet is a national scientific network
with focus on HIV/AIDS that is funded by the Feder-
al Ministry of Education and Research. In the field of
HIV/AIDS, it brings together researchers of basic
and clinical science, social sciences and public health
as well as research with special regard to children and
gender, and aims at transferring its scientific results
into clinical practice.
The KompNet cohort study was established as the
central basis for research within the network, but also
to support scientific collaborations with researchers
from outside the KompNet. By collecting a wide range
of clinical and sociodemographic data as well as bio-
materials on a regular basis [1], the main objectives of
the KompNet cohort study are (1) to monitor the epi-
demiological composition of HIV-positive patients, as
representatively as possible for the German situation,
(2) to monitor the course of HIV-infection and the ef-
September 28, 2009
Eur J Med Res (2009) 14: 415-425 ﾩ I. Holzapfel Publishers 2009
EPIDEMIOLOGICAL COMPOSITION, CLINICAL AND TREATMENT
CHARACTERISTICS OF THE PATIENT COHORT OF THE GERMAN
COMPETENCE NETWORK FOR HIV/AIDS
K. Jansen1, N. H. Brockmeyer1, 2, M. Hahn3, I. Kaul3, S. Fenske4, M. Rausch5, B. Kuhlmann6,
A. Ulmer7, E. Lauenroth-Mai8, T. Harrer9, M. Hower10, A. Skaletz-Rorowski1, C. Michalik11,
and the Competence Network for HIV/AIDS
1Kompetenznetz HIV/AIDS, 2Dermatologische Klinik, Ruhr-Universit￤t, Bochum;
3IMSIE, Institut f￼r Medizinische Statistik, Informatik und Epidemiologie, K￶ln,
4ICH Grindelpraxis, Infektionsepidemiologisches Centrum, Hamburg,
5Gemeinschaftspraxis Fuggerstra￟e, Berlin,
6Praxis Georgstra￟e, Hannover,
7Gemeinschaftspaxis Ulmer/Frietsch/M￼ller, Stuttgart,
8Gemeinschaftspraxis Turmstra￟e, Berlin,
9Medizinische Klinik 3, Universit￤tsklinikum, Erlangen,
10Universit￤tsklinikum, Dortmund,
11ZKS, Zentrum f￼r Klinische Studien, K￶ln
1. Jansen:Umbruchvorlage  27.08.2009  13:06 Uhr  Seite 415fects of cART, its side effects, concomitant diseases
and their treatment and to analyse underlying mecha-
nisms on national level, and (3) to provide clinical data
as well as biomaterials to scientific projects from in-
and outside the KompNet and to collaborate with
similar scientific projects, on national and international
level.
At the end of 2008, 63,500 persons infected with
HIV lived in Germany, thereof 10,500 persons with
AIDS [2]. In 2008, 2,806 newly diagnosed HIV infec-
tions were reported to the Robert Koch-Institute [3].
This number grew constantly between 2001 and 2008
from 1,443 to 2,806 per year, with a flattening since
2006. The epidemiology of HIV/AIDS in Germany is
characterised by a high proportion of men. Sex be-
tween men (MSM) is the main risk of transmission.
MSM was risk of transmission in 65% of all reported
newly diagnosed HIV-infections in 2008, followed by
heterosexual contacts (17%) and persons originating
from high prevalence countries (12%) [3]. Compared
to that, intravenous drug use was of minor impor-
tance in Germany (5%). New infections are diagnosed
predominantly in urban areas. Reported AIDS cases
declined from about 2,000 in 1995 to about 550 in
2007, but a high number of unreported cases is pre-
sumed [3]. The number of AIDS cases in 2008 is esti-
mated as about 1,100. This high number is supposed
to be caused by late testing and a late start of cART.
Following the prior use of antiretroviral therapy
(ART), the distinct more effective combined antiretro-
viral therapy (cART) was introduced in Germany
1996. After introduction of cART, the number of re-
ported AIDS cases and deaths due to AIDS in Ger-
many decreased heavily, in coincidence with an in-
creasing HIV prevalence due to increased life ex-
pectancy [3]. The current number of patients treated
with (cART) in Germany is estimated as 30,000 [4].
cART of HIV/AIDS improved distinctly within the
last years, especially in Western countries. Not only
many new and potent drugs of well known substance
classes as protease inhibitors (PI), nucleoside reverse
transcriptase inhibitors (NRTI) and non-nucleoside re-
verse transcriptase inhibitors (NNRTI) were intro-
duced, which built the basis for cART since 1996.
Also complete new substance classes were developed
and mostly brought into standard medical practice,
such as fusion inhibitors, integrase inhibitors, co-re-
ceptor antagonists and maturation inhibitors. There-
with, therapy of HIV/AIDS and its effects become
complex more than ever, affecting the clinical as well
as the psychosocial situation of the patients.
On basis of the KompNet cohort, it is possible to
study this high complexity of HIV/AIDS therapy in
Germany in its details. In this article, we present cen-
tral epidemiological, clinical and treatment characteris-
tics of the KompNet cohort.
METHODS
The KompNet cohort is an open, retrospective and
prospective, multi-center, disease-specific and nation-
wide cohort. It started enrolment patients in 2004.
The data come from and are documented by 25 sites
all over Germany.
For a detailed description as to the composition of
the cohort, recruitment procedures, documentation of
prospective and retrospective data and other method-
ological issues, please see [1].
If available at the documenting site, retrospective
data of patients are documented, containing data of
the period before enrolment of the patient into the
cohort. The retrospective documentation of data
comprises the therapy status, prescribed antiretroviral
treatment, CDC-stage, CD4 cell count/ﾵl, viral load.
For analysing the course of treatment, it is essential to
know the time point till which the patient was therapy-
na￯ve. Otherwise, analyses on the course and effects of
ART can be biased by a former, undocumented ART.
Therefore, the cohort documentation contains a vari-
able indicating whether the patient was assured thera-
py-na￯ve at first documentation of data or not. By
now, therapy status at start of medical care at the cur-
rently documenting site is not known for a subgroup
of patients, e.g. because this patients were treated in
another institution before attending the current docu-
menting site. Missing data on therapy status at first
documentation in the cohort is under ongoing evalua-
tion in collaboration with the documenting sites. For
all analyses referring to the time point of initial thera-
py, only patients with assured documented ART-
naivety were eligible.
Student’s t-test and χ2-tests were used to compare
groups.
State of date for all analyses was 20.10.2008.
RESULTS
DESCRIPTION OF RECRUITMENT
Enrolment of the first patient took place in April
2004. The cohort covers a total of 15,541 patients, re-
ported by 44 documenting sites over time. After a
process of reduction in 2007, the KompNet cohort
consists of 25 documenting sites currently [1], cover-
ing a total of 9,410 patients. Of these, 8,223 patients
were reported as having an ongoing documentation
since inclusion into cohort till state of date
20.10.2008.1 The number of newly recruited patients
decreased due to a recruitment stop in 2008 (Table 1).
The number of documented patients (including retro-
spective data) increased over the years till 2006 (Fig.
1). The number of patients documented prospectively
increased till 2007 (Table 1).
The proportion of patients having retrospective
documentation of data was 89.8%, independently
from the covered period of retrospective documenta-
tion. The population of 9,410 patients of the current-
ly documenting sites contributed 24,117 person-years
prospectively (mean: 2.6 years). 62,862 person-years
were documented including retrospective data (mean:
6.7 years), thereof 6,995 person-years of treatment-
na￯ve periods and 55,867 person-years under cART,
the latter including 3,776 person-years of treatment
interruptions.
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1Compared to numbers reported in [1], the number of pa-
tients reported as actively under follow-up was reduced by
four patients due to lost to follow-up.
1. Jansen:Umbruchvorlage  27.08.2009  13:06 Uhr  Seite 416EUROPEAN JOURNAL OF MEDICAL RESEARCH September 28, 2009 417
Fig. 1. Number of documented patients, distribution of sex, including retrospective data, 1990-2008, by year (N = 9,410).
Table 1. Recruitment and sociodemographic characteristics of patients being under follow-up at the respective year since enrol-
ment, 2004-2008, by year (N = 9,410).
Year
2004 2005 2006 2007 2008
No. of newly recruited patients1 1,991 3,966 2,531 876 46
Proportion of men (%) 84.5 85.4 85.6 83.3 91.3
Mean duration since first positive HIV- 8.0 8,2 7,2 5,5 4,4
diagnosis to enrolment (years, IQR) (3.1-12.0) (2.9-12.4) (1.9-10.9) (0.5-9.0) (0.5-7.6)
No. of patients followed up prospectively 1,991 5,952 8,395 8,886 8,367
Proportion of men (%) 84.5 85.1 85.2 85.1 84.8
Proportion of deaths (%) 0 0.3 0.7 0.8 0.3
Proportion of losses to follow up (%) 0 1.1 3.8 5.5 1.4
Proportion of patients treated at
Clinics (%) 58.9 33.4 26.7 26.6 26.5
Private practices (%) 41.1 66.6 73.3 73.4 73.5
Mean age at enrolment
Men (years, IQR)2 45.2 43.8 42.3 41.3 43.5
(37.6-51.6) (37.2-49.1) (36.5-47.5) (34.9-46.3) (38.4-48.3)
Women (years, IQR) 41.4 40.0 39.5 39.2 31.6
(33.5-46.9) (32.8-44.6) (32.7-44.5) (31.9-45.9) (21.5-41.7)
Vocational situation of male patients
Fully employed (> 34 h/week) 18.3 38.3 40.6 41.4 42.8
Part time work (15-34 h/week) 0.5 4.2 5.0 5.4 5.3
Work by the hour (< 15 h/week) 0.3 2.4 2.6 2.7 2.8
Not employed 10.8 33.9 33.5 32.2 31.3
Other 0.9 1.1 1.0 1.0 1.7
Not known 69.2 20.1 17.3 17.3 16.1
Vocational situation of female patients
Fully employed (> 34 h/week) 9.1 17.9 18.7 20.3 21.0
Part time work (15-34 h/week) 2.0 11.3 12.9 13.1 13.9
Work by the hour (< 15 h/week) 0 3.9 4.6 4.3 4.9
Not employed 14.1 45.4 43.2 43.7 42.4
Other 1.0 2.1 1.9 1.2 1.8
Not known 73.8 19.4 18.7 17.4 16.0
1Low number of newly recruited patients in 2008 due to a recruitment stop in 2008.
2IQR: Inter Quartile Range (25%-75%).
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175 deaths (1.9%) were registered. 55.6% of all losses
to follow up were due to a known change to another
treating institution not participating in the KompNet
cohort. Death- and lost to follow up-rates increased
over the years (Table 1). The mean duration since the
first positive HIV-diagnosis to enrolment into the co-
hort decreased strongly over time Table 1).
SOCIODEMOGRAPHIC CHARACTERISTICS
84.9% of the enrolled patients were men; the sex dis-
tribution stayed stable over the years regarding the pa-
tient population with documented retrospective data
(Fig. 1), the population of newly recruited patients as
well as the population of patients followed up prospec-
tively (Table 1). The proportion of women fluctuated
between about 15% and 17% regarding these three
populations.
The mean age at enrolment fluctuated between 41
to 45 years2 in men and 39 to 41 years in women (with
exception of 2008 with very few newly recruited
women, Table 1). The mean age differed between men
(46, IQR: 40-52) and women (43, IQR: 36-48),
p<0.001).The distribution of age groups changed over
the years towards groups of higher age (Fig. 2). The
proportion of patients being older than 49 years in
2008 was 28.1%.
Main risk of transmission was sex between men
(MSM) (Fig. 3). The proportion of intravenous drug
users (IVDU) decreased over time, the proportion of
patients coming from high prevalence countries (HPL)
as well as patients infected by heterosexual contacts in-
creased.
Most frequent country of origin of patients was
Germany with a proportion between 81.9% and
86.4% and a light decrease over the years; proportions
of patients originating from Central/Eastern Euro-
pean states (3.1% to 4.0%) as well as Sub-Saharan
countries (2.6% to 4.7%) increased lightly
(Fig. 4). There were distinct differences regarding the
migration background (country of origin other
than Germany) between men and women: 14.4% of
men, but 38.2% of women (p<0.001) were migrated,
with special emphasis of Subsaharan and Asian coun-
tries in women [1]. The federal states of Bavaria,
Berlin, Northrhine-Westfalia, and Hamburg covered
85.8% of all patients with ongoing documentation
(Table 2).
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Fig. 2. Distribution
of age groups, includ-
ing retrospective
data, 1990-2008, by
year (N = 9,410).
Fig. 3. Distribution
of risk of transmis-
sion, including retro-
spective data, 1990-
2008, by year (N =
9,410).
2Reference date for calculation of age: August 1st.
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tween sexes regarding the vocational situation (Table
1). About double as much men as women were fully
employed. About a third of men and more than 40%
of women were unemployed over the years (with ex-
ception of 2004 with a high proportion of missing
data on vocational situation).
CLINICAL DATA AND ANTIRETROVIRAL THERAPY
With exception of 2004, the proportion of patients
treated by specialised private practitioners was be-
tween 67% and 74% (Table 1).
Stable over time, nearly half of all patients were
classified as CDC-stage B, about a quarter as CDC-
stages A or C, each (Fig. 5). Regarding the risk of
transmission, IVDU had the lowest proportion
(21.1%) of patients classified as CDC-stage A (Table
3). With 40.7%, patients originating from HPL
were classified distinct more frequent as CDC-stage A
than patients having another risk of transmission.
The mean age at HIV-diagnosis was lower in women
(32, IQR: 25-37) as in men (36, IQR: 29-41, p
<0.001).
Prevalence of Hepatitis B coinfection varied be-
tween 1.6% in IVDU (6.3% Hepatitis B/C coinfec-
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Table 2. Geographical distribution of the KompNet cohort, all patients and patients under follow up at 20.10.2008.
Number of patients (%)
Federal State All patients Patients under follow-up
Baden-Wurttemberg 354 (3.8) 342 (4.1)
Bavaria 1,729 (18.4) 1,572 (19.1)
Berlin 2,985 (31.7) 2,460 (29.9)
Hamburg 1,567 (16.7) 1,449 (17.6)
Hesse 134 (1.4) 95 (1.1)
Northrhine-Westfalia 1,801 (19.1) 4,564 (19.2)
Lower Saxony 754 (8.0) 660 (8.0)
Rhineland-Palatinate 86 (0.9) 81 (1.0)
Total 9,410 (100.0) 8,223 (100.0)
Fig. 4. Distribution of
country of origin, includ-
ing retrospective data,
1990-2008, by year (N =
9,410).
Fig. 5. Distribution of
CDC-stage, including
retrospective data, 1995-
2008, by year (N =
9,410).
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lence of Hepatitis C coinfection varied heavily be-
tween 4.5% in HPL and 71.2% in IVDU.
Of 4,944 patients, the therapy status (therapy-na￯ve
or not) at start of documentation was given. 83.1%
were therapy-na￯ve at start of documentation, so the
complete cART-history of this subpopulation could be
documented. The proportion of patients under treat-
ment increased over time; the proportion of patients
having a treatment interruption increased, also (Fig. 6)3.
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Table 3. Baseline clinical and treatment characteristics of patients under follow-up at 20.10.2008, by risk of transmission (N = 8,213).
Risk of transmission
Hetero HPL IVDU MSM
Proportions of risk of transmission (%)1 18.4 5.2 7.0 63.0
Current CDC-stage (%)
A 31.1 40.7 23.1 28.2
B 43.4 33.4 51.1 46.4
C 25.5 25.9 25.8 25.4
Prevalence of Hepatitis-Co-Infections (%, N= 6,279)2
Hepatitis B 3.4 7.3 1.6 5.5
Hepatitis C 11.4 4.5 71.2 6.5
Hepatits B + C 1.0 0.3 6.3 0.7
Mean CD4 cell count/ﾵl at date of first documentation (IQR) 327 298 370 387
(123-479) (109-400) (170–500) (179-536)
Mean CD4 cell count/ﾵl of currently treated patients (IQR) 533 490 480 553
(331-670) (334-630) (266-591) (362-698)
Number of treated patients documented as assured therapy-
na￯ve at start of documentation (N= 3,230; %)3 655 222 213 2140
(20.3) (6.9) (6.6) (66.2)
Mean CD4 cell count/ﾵl at start of initial ART, (IQR) 288 258 319 301
(138-403) (110-375) (170-420) (170-394)
Mean HIV RNA at start of initial ART, mean log copies/ml (IQR) 4.0 4.1 3.8 4.3
(3.0-5.1) (3.2-5.1) (2.7-5.0) (3.5-5.2)
Proportion of patients having CD4 cell count/ﾵl <150 at start of
initial ART (%) 26.0 33.6 20.6 20.5
1Other risks of transmission low frequent and not showed, multiple answers possible.
2N reduced to 6,279; for 1,944 patients no data on tests for Hepatitis B/C available; prevalences including acute and chronic
Hepatitis as well as state after Hepatitis B/C (tested serologically).
3Only patients being documented as assured therapy-na￯ve at start of documentation were eligible for analyses regarding start of
initial ART.
Fig. 6. Therapy status
including retrospective
data,1990-2008,by year
(N = 9,410)3.
3Patients that were under treatment and had a treatment in-
terruption in the same year were numbered among patients
having a treatment interruption; patients that were na￯ve and
started a treatment were numbered among treated patients re-
garding the year of their initial therapy.
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tus by risk of transmission, except a slightly higher
proportion of therapy-na￯ve patients in MSM
(Fig. 7).
The current number of assured documented initially
treated patients was 3,265. The distribution of risk of
transmission regarding treated patients with assured
documented therapy-naivety equals the overall distrib-
ution of risk of transmission (Table 3). The mean du-
ration between first positive HIV-diagnosis and start of
initial ART fluctuated between 2.5 years and 5.3 years
with a distinct increase in 2007 (Fig. 8). There were no
significant differences regarding the this duration be-
tween men (3.3 years, IQR: 0.2-4.7) and women (3.7
years, IQR: 0.2-5.6, p = 0.06). The mean age at start of
initial therapy differed between men (40, IQR: 33-46)
and women (36, IQR: 29-41), p<0.001).
The mean CD4 cell count/ﾵl at date of first docu-
mentation fluctuated between 275 and 448 and in-
creased over time (Fig. 9). HPL had the lowest mean
CD4 cell count/ﾵl at date of first documentation (298,
Table 3), MSM the highest (387). The mean CD4 cell
count/ﾵl of currently treated patients differed not sig-
nificantly between men (538, IQR: 348-683) and
women (518, IQR: 334-669, p = 0.06) It varied be-
tween 217 in 1995 and 548 in 2008, and increased
since 1996 (Fig. 10). Regarding risk of transmission,
IVDU had the lowest mean CD4 cell count/ﾵl of cur-
rently treated patients (480, Table 3), MSM the highest
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Fig. 7. Therapy status of patients under follow up at
20.10.2008, by risk of transmission (N = 8,213).
Fig. 8. Mean duration be-
tween first positive HIV-
test and start of initial
ART, including retrospec-
tive data, 1995-2008, by
year (N = 3,265).
Fig. 9. Mean CD4-cell
count/ﾵl at date of first
documentation and pro-
portion of patients having
CD4 cell count/ﾵl <150
at start of initial therapy,
including retrospective
data, 1995-2008, by year
(NCD4 cell count/ﾵl = 4,937;
NProportion CD4 cell count/ﾵl <150
= 2,082). µl µl
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detection limit in currently treated patients differed
not significantly between sexes (men: 78.6%, women:
76.3%, p = 0.1).
Of about two third of all patients being assured
documented as initially treated, data on CD4 cell
count/ﾵl (63.2%) and viral load (59.2%) at initial ther-
apy were documented. The mean CD4 cell count/ﾵl at
start of initial ART differed not significantly between
men (292, IQR: 159-389) and women (315, IQR: 155-
423, p = 0.06) and fluctuated over the years (Fig. 11).
After a rather low level between 2003 and 2006, it in-
creased distinctly. There were no major differences be-
tween risks of transmission, excepting patients origi-
nating from HPL having a lower mean (Table 3). The
mean of HIV RNA log copies/ml stayed stable be-
tween about 4 and 4.5 log copies over time (Fig. 11)
and differed slightly between the sexes(men: 4.2, IQR:
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Table 4. Distribution of ART-regimens with frequency ≥1% of patients being under treatment (not na￯ve, no treatment inter-
ruption) and under follow up at 20.10.2008, frequency of prescribed substance classes, proportion of class-saving regimens, pro-
portion of viral load below detection limit of regimens and classes (N = 6,655).
Proportion (%) VL < detection limit (%)
Regimen
2 NRTI + 1 PI + rtv 35.5 76.1
2 NRTI + 1 NNRTI 35.9 88.0
3 NRTI 5.2 77.7
3 NRTI + 1 PI + rtv 4.7 69.7
2 PI + rtv 2.6 67.9
4 NRTI 1.7 60.3
3 NRTI + 1 NNRTI 1.7 85.8
2 NRTI + 1 NNRTI + 1 PI +rtv 1.0 79.4
2 NRTI + 2 PI + rtv 1.0 65.6
1 NRTI+ 1 PI + rtv 1.0 78.1
1 PI + rtv 1.0 64.2
other 8.7 ---
Substance classes
NRTI 90.7 79.6
NNRTI 39.5 87.4
PI 50.4 74.1
Fusion-Inhibitors 1.2 62.7
Entry-Inhibitors 0.5 50.0
Integrase-Inhibitors 1.7 54.5
Maturation-Inhibitors --- ---
Class-saving regimen
total 10.6 70.5
solely NRTI 7.4 71.3
solely PI 3.2 68.6
Fig. 10. Mean CD4 cell
count/ﾵl of treated pa-
tients, including retro-
spective data, 1990-2008,
by year (N = 6,655).
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garding the risk of transmission, there were no consid-
erable differences (Table 3). The proportion of pa-
tients having CD4 cell count/ﾵl <150 at start of initial
ART varied mainly between 20% and 30% over time
(Fig. 9). This applied also to the distribution regarding
risks of transmission, with the highest proportion in
patients originating from HPL (Table 3).
The distribution of cART of currently treated pa-
tients showed two main regimens: 2NRTI/1PI+rtv
and 2NRTI/1NNRTI (Table 4). The population being
treated with 2NRTI/1NNRTI had the highest propor-
tion of patients with viral load below detection limi
(88.0% ).
NRTI were used in 90.7% of all regimen; fusion in-
hibitors, entry-inhibitors, Integrase-inhibitors and mat-
uration inhibitors were used seldom (Table 4). About
ten percent of class-saving regimen were prescribed
currently, dominated by NRTI (Table 4).
DISCUSSION
Currently, the KompNet cohort covered about a quar-
ter of all treated HIV-positive patients in Germany,
which were estimated as about 30,000 in 2008 [4].
Regarding the geographical distribution and the
specialities of the documenting sites, central epidemi-
ological and clinical characteristics of its patients,
and considering the special characteristics of a co-
hort recruiting patients via treating institutions, the
KompNet cohort is quite representative for the
German epidemiological and treatment situation
[1].
The lower number of newly recruited patients in
2007 and 2008 were due to a temporarily lowered re-
cruitment following a cohort size reduction in 2007
[1]. It caused a decrease of patients followed up in
2007 and 2008. The cohort recruits new patients to
picture current trends of epidemiology and treatment
in Germany. Starting 2009, patients are recruited, pre-
senting treatment-na￯ve at the sites since 2008, to be
able to picture recent initial therapy regimen.
The death- and lost to follow up-rates of the Komp-
Net cohort were considerably below rates of other
comparable cohorts [5, 6, 7, 8, 9], because most pa-
tients were recruited not until 2005/2006. Over time,
we expect an increase of these rates. Their drop in 2008
is because only 56.3% of all patients had already a com-
plete documented follow-up for 2008 at state of date.
The mean duration between the first positive HIV-
test and enrolment into the cohort decreased over
time. Therewith, the overall population encloses more
patients having shorter durations of infection, an im-
portant condition to picture recent, especially initial,
treatment strategies.
The sex distribution stayed stable over time, regard-
ing the prospectively and retrospectively documented
population. It represented the epidemiological situa-
tion in Germany well [1, 3]. This applied also to the
distribution of risk of transmission with MSM as
most frequent risk by far, the declining proportion of
IVDU and the growing proportion of patients origi-
nating from HPL [1, 3]. The latter was reflected by a
growing proportion of patients with nationality of
Subsaharan countries. Nevertheless, due to a partly
high threshold for access and difficulties in recruiting
migrants not originating from Western countries for a
surveillance system like a cohort, the proportion of
migrants and patients coming from high prevalence
countries in the KompNet cohort is only half of the
proportion of the data on newly diagnosed infections,
for both sexes [1, 10, 11]
The changes of age distribution towards higher age
groups over time were due to the retrospective docu-
mentation of the population that was recruited since
2004 and reflected similar changes in the epidemiolog-
ical situation in Germany [1, 3]. With a mean age of
more than 40 years at enrolment and currently about
60% of patients between 30 to 50 years of age, the
population of the KompNet cohort reflects the epi-
demiological situation in Germany as well [1]. The vo-
cational situation is characterised by high proportions
of unemployed persons, especially in women. There
were significant correlations between stage of disease
and income situation within the cohort [12].
The proportions of cohort patients being treated in
clinics and by private practitioners were similar to the
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Fig. 11. Mean HIV RNA
log copies/ml and mean
CD4 cell count/ﾵl at
start of initial therapy, in-
cluding retrospective
data, 1995-2008, by year
(NHIV RNA Copies = 1,933;
NCD4cell count/ﾵl = 2,063).
4Viral loads of patients below detection limit were calculated
as detection limit-1, depending on the specific test.
µl
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in Germany [1]. There were differences regarding so-
ciodemographic and clinical characteristics of the pa-
tient populations of both types, but only minor dis-
parities regarding central clinical outcomes [13]. The
high proportion of patients classified as CDC-stage B
within the population is coherent for a cohort that re-
cruits patients by treating institutions [1]. The high
proportion of HPL classified as CDC-stage A was re-
markable and will be analysed further. The propor-
tions of Hepatitis B and C-confections within the sev-
eral groups at risk reflected general epidemiological
trends in that groups of HIV-positive patients [14, 15,
16, 17]. The high proportion of Hepatitis C-coinfec-
tions in patients infected by heterosexual contacts is
assumed to often unreported risk of IVDU in that
subpopulation.
Retrospectively documented data on central clinical
parameters (CDC-stage, CD-4 cell count/ ﾵl, viral
load) are under constant completion by the document-
ing sites. Of about two third of all patients being as-
sured documented as initially treated, data on CD4 cell
count/ml and viral load at the time point of the initial
therapy was documented. Due to missing values re-
garding early years of documentation, the figures on
CDC-stage, CD-4 cell count/ﾵl, and viral load con-
cerning initially treated patients pictured the time-
frame between 1995-2008 to ensure meaningful num-
bers.
The proportion of patients under treatment within
the cohort increased heavily over time, especially in
the consequence of introduction of cART (combined
antiretroviral therapy) in Germany in 1996. The dis-
tinct increase of the mean CD4 cell count/ﾵl of cur-
rently treated patients between 1996 and 2001 pictures
the introduction of cART and the improvement of its
clinical effectivity. In the following, the curve re-
mained mainly stable with an only light increase. The
lower mean CD4 cell count/ﾵl of currently treated pa-
tients in patients originating from HPL and IVDU
probably reflects impairments as to access to treat-
ment respectively as to compliance in these popula-
tions [10, 11].
The increase of the mean CD4 cell count/ﾵl at first
documentation at the documenting site can be inter-
preted as a hint for an earlier presentation of the pa-
tients at the documenting site. Following that reason-
ing, patients originating from HPL having the lowest
mean presented later; MSM and IVDU, both with dis-
tinct higher means presented earlier at the document-
ing site. Detailed analyses of late presenters within the
KompNet cohort endorsed this assumption [18]. Re-
garding IVDU being in clinical care, the often fre-
quent clinical monitoring and testing for HIV can as-
sumed as reason for that; as to MSM, there is evidence
for a high knowledge on the risks of HIV infection
and the importance of regular HIV-testing in Ger-
many [19].
Further, the increase of the mean CD4 cell
count/ﾵl at first documentation at the documenting
site corresponded to the increase of the mean dura-
tion between the first positive HIV-diagnosis and the
start of the initial ART: with higher CD4 cell
count/ﾵl, ART can be initiated later. This applied also
to the higher mean CD4 cell count/ﾵl at date of first
documentation in MSM and the higher proportion of
treatment-na￯ve patients in this group.
The increase of the mean CD4 cell count/ﾵl at start
of the initial ART after 2006 indicates a tendency to-
wards an earlier start of ART since that time point.
The low mean in patients originating from HPL and
their high proportion in patients having a CD4 cell
count/ﾵl <150 at start of the initial ART did not equal
their distribution regarding CDC-stages. This has to
be investigated further. The proportion of patients
having CD4 cell count/ﾵl below 150, varying mainly
between 20% and 30% over time, was high and did
not comply with current national and international
treatment guidelines [20, 21, 22].
According to these guidelines, there were two main
treatment regimens documented for currently treated
patients: two NRTI as backbone combined with one
NNRTI or one boostered PI, covering more than 70%
of all regimens. NRTI as backbone were used in nearly
all therapies, PI in half of all cases. The new substance
classes fusion inhibitors, entry-inhibitors, Integrase-in-
hibitors and maturation inhibitors were reported only
seldom, most frequent Integrase-inhabitors. Ten per-
cent of all currently treated patients received class-sav-
ing regimens, dominated by NRTI. Overall, the pro-
portion of patients having a viral load below detection
limit were highest in patients being treated with NNR-
TI, though not corrected for influencing factors like
number of regimens before, sex, CDC-stage etc. In
Germany, patients having a more progredient HIV-in-
fection are more likely to be treated with PI-based reg-
imens, so this might be an important influencing fac-
tor [20].
In summary, the KompNet cohort is an extensive
instrument to measure the epidemiology of patients
being in clinical care in Germany, the prescribing prac-
tices of ART and aspects of pharmacovigilance na-
tionwide, imaging the German treatment specifics and
their outcomes. The cohort includes many elder pa-
tients, which is important to analyse the special impact
of ART and its side effects within a currently ageing
HIV-population. It contains relevant numbers of
women and migrants for analyses of subpopulations.
Therewith, the KompNet cohort is of high impact as
a complement of the German surveillance instru-
ments regarding HIV/AIDS.
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